GlassScriptPhysician profile
Ashley Shaver
NPI 1932829009
$3,726.97
in general payments reported to CMS, 2019-2025
27 companies · $2,213 in 2025
The $2,213 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $639 · 2024: $875 · 2025: $2,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $766.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $594.35 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $451.00 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $339.09 | 2023-2025 | |
| Lilly USA, LLC | $336.99 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $309.85 | 2023-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Ardelyx, INC. | $141.37 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $103.24 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $102.38 | 2023-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $89.34 | 2023-2025 | Rexulti |
| Lundbeck LLC | $83.35 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $45.91 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $44.72 | 2023 | |
| Novartis Pharmaceuticals Corporation | $44.50 | 2024-2025 | |
| Lucid Diagnostics INC. | $37.23 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.61 | 2024-2025 | Otezla, Repatha, Repatha |
| Axsome Therapeutics, INC. | $23.95 | 2025 | Symbravo |
| Alnylam Pharmaceuticals INC. | $22.73 | 2025 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.19 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.04 | 2025 | Jardiance |
| Corcept Therapeutics | $19.66 | 2025 | Korlym |
| Collegium Pharmaceutical, INC. | $19.53 | 2023 | Xtampza |
| Medtronic, INC. | $18.25 | 2024 | Minimed 780g |
| Idorsia Pharmaceuticals US INC | $16.57 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $16.37 | 2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $15.50 | 2025 | Zoryve |
| Echosens North America, INC. | $7.76 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.